The aim of the study is to compare the risk of acromegaly patients developing valvular regurgitation when receiving lanreotide or octreotide

Inclusion Criteria:

• Patient has a diagnosis of Acromegaly
• Patient is being treated with lanreotide or octreotide in any dose form at the selection visit or is a de novo patient who is due to commence treatment within 2 weeks of baseline
• Patient started treatment with either lanreotide or octreotide when both products were available on the market in their country
• Patient must not change treatment form lanreotide to octreotide or vice versa for the duration of the study

Exclusion Criteria:

• Patients with known significant valve abnormalities prior to treatment with either lanreotide or octreotide
• Patients who have received treatment with a somatostatin analogue other than lanreotide or octreotide for more than 3 months
• Patients who have received treatment with a GH antagonist for more than 3 months
• Patients who have had heart valve replacement therapy